BriaCell's Bria-IMT Shows Durable Survival, QOL Benefits in Breast Cancer Data at ASCO 2026
BCTX sits 23% above its 52-week low of $2.98.
Summary
BriaCell presented positive clinical data for its Bria-IMT™ immunotherapy at ASCO 2026, highlighting durable survival rates and quality of life benefits for advanced breast cancer patients. The data showed 44% 12-month and 26% 24-month survival rates in heavily pretreated metastatic breast cancer patients, alongside preserved quality of life and a tolerable safety profile. This follows earlier announcements about presenting data and previous positive QOL and biomarker data, providing more specific and detailed results. These findings are highly significant for a clinical-stage biotech, especially given the company's recent going concern warning, and could support the ongoing pivotal Phase 3 study and future regulatory efforts.
At the time of this announcement, BCTX was trading at $3.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27M. The 52-week trading range was $2.98 to $37.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.